These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 17026488

  • 1. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
    [Abstract] [Full Text] [Related]

  • 2. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
    Bosi E, Ellis GC, Wilson CA, Fleck PR.
    Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
    [Abstract] [Full Text] [Related]

  • 7. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 8. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients.
    Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR.
    Diabetes Obes Metab; 2011 Nov; 13(11):1036-46. PubMed ID: 21682834
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial.
    Cai XL, Chen YL, Zhao JJ, Shan ZY, Qiu MC, Li CJ, Gu W, Tian HM, Yang HZ, Xue YM, Yang JK, Hong TP, Ji LN.
    Chin Med J (Engl); 2015 May 20; 128(10):1279-87. PubMed ID: 25963345
    [Abstract] [Full Text] [Related]

  • 10. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May 20; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 20; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 12. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.
    Clin Ther; 2007 Sep 20; 29(9):1900-14. PubMed ID: 18035190
    [Abstract] [Full Text] [Related]

  • 13. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
    Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A.
    Diabetes Obes Metab; 2008 Sep 20; 10(10):862-73. PubMed ID: 18201206
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G, Institution Investigators.
    Diabetes Obes Metab; 2012 Aug 20; 14(8):737-44. PubMed ID: 22369287
    [Abstract] [Full Text] [Related]

  • 15. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A.
    Diabetes Obes Metab; 2009 Apr 20; 11(4):379-86. PubMed ID: 19087105
    [Abstract] [Full Text] [Related]

  • 16. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
    Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR.
    Curr Med Res Opin; 2006 Sep 20; 22(9):1715-23. PubMed ID: 16968575
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA, Sautter M, Van Gaal LF, Jones NP.
    Diabetes Obes Metab; 2003 May 20; 5(3):163-70. PubMed ID: 12681023
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.